Consistency of continual reassessment method under model misspecification

DOI10.1093/BIOMET/83.2.395zbMATH Open1059.62710OpenAlexW2075236916MaRDI QIDQ3837320FDOQ3837320

Authors: Larry Zaiqian Shen, John O'Quigley 

Publication date: 1996

Published in: Biometrika (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1093/biomet/83.2.395

Recommendations

• On the consistency of the continual reassessment method with multiple toxicity constraints
• A note on the robustness of the continual reassessment method
• A simple technique to evaluate model sensitivity in the continual reassessment method
• Continual reassessment and related dose-finding designs
• Miscellanea. A stopping rule for the continual reassessment method

zbMATH Keywords

Sequential designModel misspecificationDiscrete barrierDose-toxicity curve

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Cited In (32)

• Convergence properties of sequential Bayesian \(D\)-optimal designs
• Dose-finding designs for HIV studies
• Impact of different model structure and prior distribution in continual reassessment method
• A simple technique to evaluate model sensitivity in the continual reassessment method
• A note on the robustness of the continual reassessment method
• The treatment versus experimentation dilemma in dose finding studies
• A new design of the continual reassessment method
• On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance
• A note on continual reassessment method
• Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
• Title not available (Why is that?)
• Continual reassessment method for ordered groups
• A simulation-free approach to assessing the performance of the continual reassessment method
• Change-point joint model for identification of plateau of activity in early phase trials
• Highest dose level for non-increased-toxicity response in longitudinal data
• Incorporating patient-reported outcomes in dose-finding clinical trials
• Consistency of the when the curve is not monotone and its application to the POCRM
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD
• Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
• Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
• Theoretical study of the continual reassessment method
• Adaptive clinical trial designs for phase I cancer studies
• Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
• Retrospective Analysis of Sequential Dose‐Finding Designs
• On the consistency of the continual reassessment method with multiple toxicity constraints
• Curve-free and model-based continual reassessment method designs
• Performance Measures in Dose‐Finding Experiments
• Dynamic calibration of pharmacokinetic parameters in dose-finding studies
• Characterization of the likelihood continual reassessment method
• Stochastic approximation and modern model-based designs for dose-finding clinical trials
• A study of the probit model with latent variables in Phase I clinical trials
• Title not available (Why is that?)

This page was built for publication: Consistency of continual reassessment method under model misspecification

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3837320)